Douglas Cole Net Worth

The estimated Net Worth of Douglas G. Cole is at least $3.16 Million dollars as of 1 June 2021. Mr. Cole owns over 3,253 units of Denali Therapeutics Inc stock worth over $88,091 and over the last 15 years he sold DNLI stock worth over $2,667,000. In addition, he makes $402,576 as Independent Director at Denali Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Cole DNLI stock SEC Form 4 insiders trading

Douglas has made over 2 trades of the Denali Therapeutics Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 3,253 units of DNLI stock worth $88,091 on 1 June 2021.

The largest trade he's ever made was selling 150,000 units of Denali Therapeutics Inc stock on 12 May 2011 worth over $2,667,000. On average, Douglas trades about 3,483 units every 83 days since 2010. As of 1 June 2021 he still owns at least 3,253 units of Denali Therapeutics Inc stock.

You can see the complete history of Mr. Cole stock trades at the bottom of the page.

Douglas Cole biography

Douglas Cole M.D. serves as Independent Director of the Company. Dr. Cole joined Flagship Pioneering, which conceives, creates, resources and develops first-in-category life sciences companies, in 2001, and is currently a Managing Partner focused on life science investments. Dr. Cole currently serves on the board of directors of a number of private companies. Previously, Dr. Cole served on the boards of directors of a number of public companies including Quanterix Corporation, Agios Pharmaceuticals, Receptos, AVEO Pharmaceuticals, Editas Medicine, Tetraphase Pharmaceuticals and Concert Pharmaceuticals. Dr. Cole received his M.D. from the University of Pennsylvania School of Medicine and his B.A. in English from Dartmouth College.

What is the salary of Douglas Cole?

As the Independent Director of Denali Therapeutics Inc, the total compensation of Douglas Cole at Denali Therapeutics Inc is $402,576. There are 13 executives at Denali Therapeutics Inc getting paid more, with Ryan Watts having the highest compensation of $4,978,610.

How old is Douglas Cole?

Douglas Cole is 59, he's been the Independent Director of Denali Therapeutics Inc since 2015. There are 6 older and 13 younger executives at Denali Therapeutics Inc. The oldest executive at Denali Therapeutics Inc is Vicki Sato, 71, who is the Independent Chairman of the Board.

What's Douglas Cole's mailing address?

Douglas's mailing address filed with the SEC is 500 TECHNOLOGY SQUARE, STE 700, CAMBRIDGE, MA, 02139.

Insiders trading at Denali Therapeutics Inc

Over the last 7 years, insiders at Denali Therapeutics Inc have traded over $438,930,443 worth of Denali Therapeutics Inc stock and bought 275,000 units worth $4,950,000 . The most active insiders traders include Llc Fmr, Douglas Kakdl, L.P.Crestlin..., and Jay T Flatley. On average, Denali Therapeutics Inc executives and independent directors trade stock every 11 days with the average trade being worth of $1,606,006. The most recent stock trade was executed by Vicki L Sato on 3 September 2024, trading 3,080 units of DNLI stock currently worth $77,000.

What does Denali Therapeutics Inc do?

denali therapeutics inc. (“denali”) is a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative diseases, including alzheimer’s disease, parkinson’s disease, als and others. denali was founded by scientists, industry experts and investors who share the vision that recent scientific insights into the genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, offer an unprecedented opportunity to discover and develop effective medicines. denali is rigorously pursuing a science-driven approach to translational medicine and clinical development. founding investors include fidelity biosciences, arch venture partners, flagship ventures and the alaska permanent fund (represented by crestline investors).

Complete history of Mr. Cole stock trades at Agios Pharmaceuticals Inc, AVEO Pharmaceuticals Inc, Editas Medicine Inc, Tetraphase Pharmaceuticals, Quanterix Corp, Denali Therapeutics Inc, Foghorn Therapeutics, and Sigilon Therapeutics

Denali Therapeutics Inc executives and stock owners

Denali Therapeutics Inc executives and other stock owners filed with the SEC include:

• Ryan Watts,
  President, Chief Executive Officer, Co-Founder, Director
• Steve Krognes,
  Chief Financial Officer, Treasurer
• Carole Ho,
  Chief Medical Officer, Head of Development
• Alexander Schuth,
  Co-Founder, Chief Operating Officer, Secretary
• Dr. Ryan J. Watts Ph.D.,
  Co-Founder, Pres, CEO & Director
• Steve Edward Krognes,
  CFO & Treasurer
• Dr. Carole Ho,
  Chief Medical Officer & Head of Devel.
• Dr. Alexander O. Schuth M.D.,
  Co-Founder, COO & Sec.
• Dr. Carole Ho M.D.,
  Chief Medical Officer & Head of Devel.
• Vicki Sato,
  Independent Chairman of the Board
• Marc Tessier-Lavignec,
  Independent Director
• Peter Klein,
  Independent Director
• David Schenkein,
  Independent Director
• Jay Flatley,
  Independent Director
• Douglas Cole,
  Independent Director
• Robert Nelsen,
  Independent Director
• Jennifer Cook,
  Independent Director
• Dr. Marc Tessier-Lavigne Ph.D.,
  Co-Founder, Chairman of Scientific Advisory Board & Independent Director
• Dr. Marc Tessier-Lavigne,
  Co-Founder, Chairman of Scientific Advisory Board & Independent Director
• Chris Walsh,
  Associate Gen. Counsel
• Dr. Laura Hansen,
  VP of Investor Relations
• Joe Lewcock,
  Chief Scientific Officer
• Dr. Dana Andersen,
  Chief Technical and Manufacturing Officer
• Tyler M. Nielsen,
  VP of Corp. Fin.
• Douglas Kakdl, L.P.Neuro Li...,
  
• Ventures Fund V, L.P.Afeyan...,
  
• Marc Tessier Lavigne,
  Director
• Ltd Fil,
  
• Llc Fmr,
  
• Venture Fund Viii, L.P.Arch...,
  
• Douglas K Neuro Line Partne...,
  
• Douglas Kakdl, L.P.Crestlin...,
  
• Nancy Thornberry,
  Director
• Erik Harris,
  Director